High systemic levels of interleukin-10, interleukin-22 and C-reactive protein in Indian patients are associated with low in vitro replication of HIV-1 subtype C viruses by Arias, Juan F et al.
RESEARCH Open Access
High systemic levels of interleukin-10, interleukin-
22 and C-reactive protein in Indian patients are
associated with low in vitro replication of HIV-1
subtype C viruses
Juan F Arias
1,2, Reiko Nishihara
3, Manju Bala
1,4, Kazuyoshi Ikuta
1*
Abstract
Background: HIV-1 subtype C (HIV-1C) accounts for almost 50% of all HIV-1 infections worldwide and
predominates in countries with the highest case-loads globally. Functional studies suggest that HIV-1C is unique in
its biological properties, and there are contradicting reports about its replicative characteristics. The present study
was conducted to evaluate whether the host cytokine environment modulates the in vitro replication capacity of
HIV-1C viruses.
Methods: A small subset of HIV-1C isolates showing efficient replication in peripheral blood mononuclear cells
(PBMC) is described, and the association of in vitro replication capacity with disease progression markers and the
host cytokine response was evaluated. Viruses were isolated from patient samples, and the corresponding in vitro
growth kinetics were determined by monitoring for p24 production. Genotype, phenotype and co-receptor usage
were determined for all isolates, while clinical category, CD4 cell counts and viral loads were recorded for all
patients. Plasmatic concentrations of cytokines and, acute-phase response, and microbial translocation markers
were determined; and the effect of cytokine treatment on in vitro replication rates was also measured.
Results: We identified a small number of viral isolates showing high in vitro replication capacity in healthy-donor
PBMC. HIV-1C usage of CXCR4 co-receptor was rare; therefore, it did not account for the differences in replication
potential observed. There was also no correlation between the in vitro replication capacity of HIV-1C isolates and
patients’ disease status. Efficient virus growth was significantly associated with low interleukin-10 (IL-10), interleukin-
22 (IL-22), and C-reactive protein (CRP) levels in plasma (p < .0001). In vitro, pretreatment of virus cultures with IL-
10 and CRP resulted in a significant reduction of virus production, whereas IL-22, which lacks action on immune
cells appears to mediate its anti-HIV effect through interaction with both IL-10 and CRP, and its own protective
effect on mucosal membranes.
Conclusions: These results indicate that high systemic levels of IL-10, CRP and IL-22 in HIV-1C-infected Indian
patients are associated with low viral replication in vitro, and that the former two have direct inhibitory effects
whereas the latter acts through downstream mechanisms that remain uncertain.
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HIV-1 subtype C is the most prevalent HIV-1 subtype
worldwide, accounting for more than 50% of HIV-1
infections worldwide in 2004 [1]. It predominates in
countries with 80% of all global HIV-1 infections (sub-
Saharan Africa, India) and is rapidly increasing in China
and Latin America [2-5]. The reasons for the increase in
HIV-1 C are not known, but may be related to host,
viral, or socioeconomic factors.
Accumulating evidence suggests that HIV-1C may be
unique in its spread and natural history, but the
mechanistic basis for these differences remains
unknown. In a West African cohort, individuals infected
with HIV-1C were reported to be more likely to develop
AIDS than those infected with HIV-1A [6]. In a Kenyan
study, patients infected with HIV-1C showed lower CD4
cell counts and higher viral loads than patients infected
with other subtypes [7]. Functional studies of HIV-1B
and other subtypes have shown that progression to
AIDS is associated with a selection of high-growth
potential viral variants that use CXCR4 as a co-receptor
[8,9]. However, HIV-1C is unique in maintaining its pre-
dominant CCR5 tropism throughout infection, which
may affect its transmission and pathogenesis [10,11],
and there are some contradicting reports about its repli-
cative properties [12,13].
Subtype differences in vitality and fitness have also
been reported. HIV-1C variants replicate less efficiently
in macrophages and PBMC when compared to subtype
B viruses, but more efficiently in Langerhans cells and
in the presence of immature dendritic cells (iDCs)
[14,15]. However, the utilization of diverse cellular sys-
tems and assays to measure phenotypic properties of R5
and ×4 HIV-1 viruses has led to substantial confusion in
the current literature, and the true biological mechan-
isms underlying subtype differences in replication capa-
city are still poorly understood.
At the viral level, it has been suggested that an extra
NF-B binding site in the long terminal repeat may
enhance gene expression, altering the transmissibility
and pathogenesis of C viruses [16,17]. Other unique bio-
logical features of HIV-1C viruses include an increased
responsiveness to cellular proteins and cytokines [18],
low frequency of sincytium inducing (SI) viruses [19]
and a number of unique subtype signatures across the
viral genome [20,21].
Conversely, the influence of host factors on determin-
ing subtype differences in replication potential has
received little attention in the literature. HIV-1 replica-
tion is under continuous regulation by a complex cyto-
kine network produced by a variety of cells, and the
impact of cytokines on HIV-1 replication has been
amply studied in myeloid cells [22]. A number of
cytokines have been reported to modulate HIV replica-
tion in vitro, with their effects being inhibitory (IFNa,
IL-10, IL-13), stimulatory (TNF, IL-1, IL-6) or bi-func-
tional (IL-4, IFNg). Furthermore, a recent report showed
that production of IL-10 in pregnant seropositive
women helped them control HIV-1 replication and
reduce the chance of transmission to the fetus [23].
Therefore, we argue that differences in the host cyto-
kine environment affect the immune activation state,
and that in turn these differences might affect the in
vitro replication capacity of HIV viruses. Consequently,
we studied whether the host cytokine environment con-
tributes to measurable differences in replication capacity
of HIV-1C viruses.
Here we identified a small number of viral isolates
showing high in vitro replication capacity in healthy-
donor PBMC. Efficient virus growth was significantly
associated with a triad of low IL-10, IL-22 and CRP
levels in plasma (p < .0001), and pretreatment of virus
cultures with IL-10 and CRP resulted in a significant
reduction of virus production in vitro. Additionally, sys-
temic IL-22 levels correlated positively with CRP and
IL-10, and negatively with plasmatic lipopolysaccharide
(LPS), an indicator of microbial translocation from the
gut; this suggests IL-22 mediates its anti-HIV effects
indirectly through interactions with IL-10 and CRP, and
also through its protective effect on epithelial function.
Taken together, these results indicate that a complex
host environment characterized by an IL-10 dominant
immunosuppressive profile that reduces immune activa-
tion, in concert with a subclinical inflammatory
response of peripheral tissues mediated by IL-22 and
CRP, appears to contribute to the observed low replica-
tion capacity of HIV-1C viruses in PBMC. Furthermore,
both IL-10 and CRP showed direct anti-HIV action in
vitro,w h e r e a sI L - 2 2g i v e ni t sl a c ko fe f f e c to ni m m u n e
cells appears to act through downstream mechanisms
that remain poorly understood.
Methods
Patients and samples
Plasma and PBMC samples were obtained from 243
HIV-1-infected patients attending the Integrated Coun-
seling and Testing Centre at Safdarjang Hospital, New
Delhi, India, between February 2006 and May 2009. Of
these, only the 85 subjects for whom successful viral iso-
lation and complete biological characterization of pri-
mary isolates was possible were included in the analysis.
All patients had a serologic diagnosis of HIV infection
established prior to inclusion in the study, and were
attending a reference center for follow-up. However,
since the number of patients who were receiving
HAART was very low in our sample, these cases were
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included in the analysis. CD4
+ T cells were counted by
flow cytometry (Becton-Dickinson, CA). Viral load was
measured by the Amplicor HIV-1 Monitor test (Hoff-
man-La Roche). The study was approved by the local
Ethics Committee, and all patients provided their writ-
ten informed consent to participate.
Virus Isolation
HIV-1 was isolated from patients peripheral blood
mononuclear cells (PBMC) when available by co-culture
with phytohemagglutinin (PHA)-activated healthy-donor
PBMC [24]. In the other cases, isolates were obtained by
culturing 100 μl of plasma overnight with PHA-activated
PBMC, as previously described [25]. Viral growth was
monitored in culture supernatants every 3 days using a
commercial p24 antigen kit (Zeptometrix, Buffalo, NY).
Titration of HIV-1 isolates
The infectivity titer for each isolate was determined by
measuring HIV p24 production after 7 days using an
endpoint dilution assay, as described in detail elsewhere
[26]. The tissue culture dose for 50% infectivity
(TCID50) was calculated using the Spearman-Karber
formula.
Viral replication kinetics
All viral isolates that replicated to at least 100 pg/ml of
p24 antigen in the initial culture were saved and further
expanded by infecting new batches of PHA-stimulated
PBMC from normal donors. The in vitro growth kinetics
of the viruses studied were determined in triplicate by
mono-infection of PBMC at a multiplicity of infection
(MOI) of 0.001 and monitoring for p24 production over
a period of 12 days post-infection (p.i.) The virus stock
was diluted to obtain a MOI of 0.001 IU/PBMC, based
on the TCID50 (IU/ml) of each viral stock and a number
of 1 × 10
6 cells, as previously described [27]
Phenotyping
Co-receptor usage was determined in human astro-
glioma U87 cell lines stably expressing CD4 and co-
expressing CCR5 or CXCR4 chemokine receptors as
described before [28]. Additionally, syncytial characteri-
zation was determined by the MT-2 syncytium-forming
assay. For this, 1 × 10
6 fresh PBMCs were co-cultivated
with 1 × 10
6 MT-2 cells, as described [29].
Genotyping
Virus genotype was determined by conventional bulk
sequence analysis of the patient samples. For this, the
pro gene (297 bp), a p24 fragment of the gag gene (450
bp), and a C2-V5 fragment of the env gene (708 bp) of
viral isolates were amplified by nested PCR and
sequenced for genotype determination. Briefly, viral
RNA was extracted from patient serum samples using
the QIAamp Blood kit (Qiagen, Chatsworth, CA), and
nested RT-PCR reactions were performed to amplify the
fragments mentioned using primer sets and cycling con-
ditions described previously [30,31]. As a positive con-
trol, we used an infectious molecular clone of Indian
HIV-1C, Indie-C1 [32]. PCR products were directly
sequenced using a Big Dye Terminator, version 1.1
(Applied Biosystems), in accordance with the manufac-
turer’s instructions. Sequences were trimmed manually
and aligned with sequences representative of the HIV-1
group M subtypes available in the Los Alamos database
using CLUSTALX [33].
Determination of cytokines, acute-phase response and
microbial translocation markers
Plasmatic concentrations -in pg/ml- of tumor necrosis
factor-alpha (TNF-a), interferon-gamma (IFNg), inter-
leukin (IL)-1, IL-4, IL-6, IL-10, IL-17, IL-22, and C-reac-
tive protein (CRP) -in μg/ml- in patients’ samples and
HIV-negative controls were determined quantitatively
using commercially available colorimetric immunoassays
(Quantikine Human Immunoassay kits) and carried out
as recommended by the manufacturer (R&D Systems,
Minneapolis, MN). Plasma LPS levels were determined
as described elsewhere [34], using the Limulus amebo-
cyte lysate assay (LAL) according to manufacturer’s
instructions (Lonza, Walkersville, MD).
Cytokine treatment of viral cultures
Healthy-donor PBMCs were pre-incubated for 1 hour at
37°C with several treatment schemes of recombinant
human IL-6, IL-10, CRP and anti-IL-10 mAb, followed
by incubation with 2 representative R/H phenotype HIV-
1C primary isolates and the infectious molecular clone
Indie-C1, at a MOI of 0.1. After incubation for 2 h, the
cells were extensively washed and cultured for 12 addi-
tional days. All treatments were added at concentrations
just high enough to elicit a maximum response, as mea-
sured by the ability to bind Fcg RIIa in case of CRP, and
in a cell proliferation assay using a factor-dependent cell
line in case of the interleukins [35,36]. The anti-IL-10
antibody was added at the Neutralization Dose50 (ND50).
Differences in virus growth compared with untreated
controls were evaluated by monitoring p24 production.
Statistical analysis
Comparisons between groups were performed using the
Pearson chi-square or Fisher’s exact test for categorical
variables. The distribution of continuous variables (viral
load, CD4 cell count, etc.) was compared between
patients with different viral replication phenotypes using
non-parametric methods (Mann-Whitney U test). The
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to analyze the correlation between the in vitro replica-
tion capacity and disease progression, cytokine produc-
tion profile and disease progression, as well as the
correlation between systemic IL-22 levels and the acute-
phase and microbial translocation markers. Use of these
non-parametric statistics was required for the analysis of
observations that were not normally distributed. Fisher’s
z transformation was used to calculate confidence inter-
vals to test the statistical significance of the correlation
coefficients (i.e., to determine the degree of confidence
that the true value of the correlation in the population
is contained within these intervals). Statistical signifi-
cance was defined as p < .05 values.
Results
Epidemiological and clinical characteristics of patients
Table 1 summarizes the epidemiologic, clinical, labora-
tory and virological data of the patients. The study sam-
ple (n = 85) comprised 53 men and 32 women with an
age distribution ranging from 10 to 55 years (mean,
33.37 years). Infection with HIV-1 occurred primarily
through heterosexual contact (82.4%), but with a clear
distinction according to gender. Transmission in men
was associated with extramarital activities, while women
acquired the virus mainly through their infected
spouses, and this difference was statistically significant
(p < .001). The mean viral load in plasma was high
(230,767 HIV-1 RNA copies/ml) consistent with
advanced HIV-1 disease, but, while the mean CD4
+ T-
cell count was low (255.6 cells/mm
3), it never fell below
AIDS levels in almost half of the patients.
A small subset of viral isolates that replicate efficiently in
PBMC
Direct co-culture of patient PBMC/plasma with healthy-
donor cells was used for viral isolation, as described in
Methods. Of the 85 co-cultures which resulted in suc-
cessful viral isolation, most (75%) became positive in ≤ 6
days and reached peaks of p24 production by day 9,
although replication patterns varied widely. As shown in
Fig. 1, thirteen isolates had a suggestive “rapid/high” (R/
H) replication phenotype, replicating quickly and to
high titers in primary and secondary expansion cultures,
reaching high levels of p24 production (mean, 1745.7
pg/ml). The other 72 isolates did not produce high
levels of virus in primary or secondary expansion cul-
tures (mean, 188.9 pg/ml), showing a suggestive “slow/
low” (S/L) replication pattern [37,38].
Biological characterization of viral isolates
A frequently cited reason for enhanced cytopathicity and
more vigorous viral replication is the development of
viral variants that use CXCR4 as co-receptor [8].
Therefore, to further characterize the biology of our
HIV-1C isolates, syncytial phenotype and co-receptor
u s a g ew e r ed e t e r m i n e db ym e a n so ft h eM T - 2s y n c y t i a l
assay and the U87.CD4 cell assay, respectively. As
shown in Table 1, all but four of the primary isolates
used in this study (n = 85) replicated more efficiently in
U87. CD4 cells expressing CCR5 than in CXCR4-
expressing cells, indicating that they are R5 tropic
viruses. The fold difference of CCR5 over CXCR4
growth was nearly 100-fold, and the HIV p24 values in
U87.CD4.CXCR4 cells were mostly below 150 pg/ml.
Consistent with CCR5 co-receptor usage, isolates were
found to be non-syncytium inducing (NSI) due to their
inability to form syncytia in MT2 cells. More impor-
tantly, the only four isolates with preferential ×4 tropism
were all S/L viruses. These results indicate that the pre-
sence of R/H isolates in our study is independent of ×4
co-receptor usage. Additionally, all HIV-1 isolates were
subtyped in the C2-V5 region of the env gene by direct
sequencing and were shown to belong to HIV-1C, the
subtype predominant in 99% of infections in India [39].
Thirty isolates were also subtyped in the pro and gag
genomic regions and shown to belong to subtype C,
suggesting that these isolates were unlikely to be inter-
subtype recombinants, although this cannot be excluded.
Efficient replication does not correlate with disease
progression
Since viral strains with high-growth potential are selected
in late-stage disease [40], we analyzed the relationship
between markers of disease progression and viral replica-
tion. We categorized disease progression in our 85 HIV-
infected patients according to viral loads [41] as well as
the 1993 CDC Classification System & Expanded AIDS
Surveillance Definition for Adolescents and Adults [42],
which classifies patients on the basis of clinical conditions
associated with HIV infection and CD4
+ T- lymphocyte
counts. Clinical status and the CDC classification results
are summarized in Table 1, whereas analysis of viral load
and CD4
+ T-cell count is shown in Fig. 2A and 2B, respec-
tively. No significant differences were found between R/H
and S/L isolates when clinical category (p = .342), virus
load (p = .455) or CD4
+ T cell category (p = .063) were
compared, suggesting similar disease status for both
groups of subjects. Additionally, correlation analysis
further showed the lack of association between replication
and viral load or CD4
+ c e l lc o u n t sa ss h o w ni nF i g .2 C
and 2D, respectively.
Replication capacity of isolates is negatively associated
with patient plasmatic IL-10, IL-22 and CRP levels
The in vitro replication capacity of the viral isolates was
determined by monitoring p24 antigen production; and
according to their p24 production profiles, two groups
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noted. When the cytokine responses were compared
between R/H and S/L isolates, we found a strong
negative association between the plasmatic levels of
IL-22 (p = .00004) and IL-10 (p = .0000007) and the in
vitro replication kinetics of HIV-1C primary isolates, as
shown in Fig. 3A and 3B, respectively (n = 85). No sta-
tistical differences in plasmatic levels of TNF-a,I F N g,
IL-4, IL-6, IL-1a, and IL-17 were observed between the
two groups, Fig. 3D through 3I. For comparison, the
plasmatic concentrations of all cytokines in 10 HIV-
uninfected healthy control subjects are shown, but as
expected most measurements fell below the detection
limit, given that the transient and paracrine character of
cytokines limits its detection in the absence of systemic
pathology [43].
Table 1 Characteristics of 85 Indian HIV-infected patients with R/H or S/L phenotype HIV-1C isolates
S/L
† group (n = 72) R/H
‡ group (n = 13) Total (n = 85) p
number (%) * number (%) * number (%) *
EpidemiologicalData
Sex 0.758
Male 44 (61.1) 9 (69.2) 53 (62.4)
Female 28 (38.9) 4 (30.8) 32 (37.6)
Age (mean years ± SEM
§) 33.7 ± 1.1 31.4 ± 1.5 33.4 ± 0.9 0.426
Transmission route 0.184
Heterosexual: extramarital 31 (43.1) 6 (46.2) 37 (43.5)
Heterosexual: infected-partner 31 (43.1) 2 (15.4) 33 (38.8)
Others 10 (13.9) 5 (38.5) 15 (17.6)
Clinical Data
Common clinical findings
Fever of Unknown Origin (FUO) 27 (37.5) 6 (46.2) 33 (38.8) 0.554
Acute febrile syndrome 23 (31.9) 8 (61.5) 31 (36.5) 0.060
Asymptomatic 17 (23.6) 3 (23.1) 20 (23.5) 1.000
Diarrea 18 (25.0) 2 (15.4) 20 (23.5) 0.724
Pulmonary TBc 17 (23.6) 2 (15.4) 19 (22.4) 0.723
Others 24 (33.3) 6 (46.2) 30 (35.3) 0.529
CDC Clinical category
1 0.342
A 27 (37.5) 4 (30.8) 31 (36.5)
B 19 (26.4) 6 (46.2) 25 (29.4)
C 26 (36.1) 3 (23.1) 29 (34.1)
CDC CD4 category
2 0.063
1 8(11.1) 2 (15.4) 10 (11.8)
2 30(41.7) 1 (7.7) 31 (36.5)
3 34(47.2) 10(76.9) 44 (51.8)
Combined CDC AIDS Category
3 41 (56.9) 10(76.9) 51 (60.0) 0.227
Virological Data
Genotype 1.000
HIV-1C 72(100) 13(100) 85(100)
Phenotype 1.000
R5 68 (94.4) 13(100) 81 (95.3)
×4 4 (5.6) 0 (0) 4 (4.7)
p24 Ag titer (pg/ml; mean ± SEM
§) 189.0 ± 5.8 1745.7 ± 64.9 427.1 ± 62.1 <0.001
¶
†S/L, Slow low viral growth phenotype;
‡R/H, Rapid high viral growth phenotype.
* The percentages were calculated by dividing the number of observations with a given characteristic by the total number of subjects in each category
1 CDC Classification System & Expanded AIDS Surveillance Definition for Adolescents and Adults. Based on 3 clinical categories; category C includes the clinical
conditions listed in the AIDS surveillance case definition.
2CDC Classification System & Expanded AIDS Surveillance Definition for Adolescents and Adults. System of 3 ranges of CD4 counts based on the lowest
documented measure; category 3 <200/μL CD4 cells.
3The definition of AIDS includes all HIV-infected individuals with CD4 counts of <200 cells/μL as well as those with the clinical conditions listed in the AIDS
surveillance case definition (categories A3, B3, and C1-C3).
¶Overall p-value less than 0.001.
§SEM, standard error of the mean.
Comparisons between groups were performed using the Pearson chi-square or Fisher’s exact test for categorical variables. The Mann-Whitney U test was used for
continuous data.
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Page 5 of 15Figure 1 Viral replication kinetics of HIV-1C isolates on PHA-activated healthy-donor PBMC. Virus replication was monitored by measuring
the amounts of p24 Gag protein produced in the culture supernatants every three days. The values given are mean ± SD of p24 antigen (pg/ml)
of either R/H isolates (open circle) or S/L isolates (filled diamond). The data are representative of the results from three independent experiments.
Figure 2 Viral load and CD4
+ T-cell count in HIV-1C-infected Indian patients. The indicated parameters were evaluated in 85 HIV-1C-
infected individuals included in this study and sorted according to viral growth phenotype. (A) Viral load (HIV RNA copies/ml plasma) in patients
with either R/H (open circle) or S/L viral isolates (filled diamond). (B) CD4
+ T-cell counts (cells/mm
3) in the same groups of patients. (C) Lack of
correlation between viral load (HIV RNA copies/ml plasma) and in vitro replication (p24, pg/ml) in the same sample. (D) Lack of correlation
between CD4
+ T-cell counts (cells/mm
3) and in vitro replication (p24, pg/ml). For panels C and D, r = Spearman correlation coefficient; p-value
(two tailed);(ns) indicates that the p-value of the correlation coefficient was more than .05 (not significant). The mean values of the
measurements obtained from two independent experiments are shown (n = 85).
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therefore it has no effect on the immune response.
However, the literature suggests that the anti-HIV activ-
ity of this cytokine could be mediated by its downstream
acute-phase products [45]. Subsequently, we measured
the plasmatic levels of the pentraxin CRP (Fig. 3C), and
found that it was also inversely associated with viral
replication (p = .0003). Nevertheless, although CRP
levels were significantly different between both R/H-
and S/L-harboring patients (mean, 39.75 and 51.35 μg/
ml, respectively), the concentrations of plasmatic CRP
found were well under 10 mg/l, and thus do not reflect
clinically significant inflammatory states, but rather a
subclinical response [46]. CRP levels in HIV-uninfected
controls (mean 1.75 μg/ml) were >20-fold lower than
the levels detected in our patient population, in accor-
dance with the low concentrations of CRP reported to
circulate in the absence of acute infective or inflamma-
tory episodes [47] and the manufacturer’sc a l i b r a t i o n
data.
Figure 3 Cytokine profile of HIV-1C infected Indian patients. The indicated cytokines, along with the inflammatory marker CRP were
evaluated by ELISA in plasma collected from HIV-1C-infected patients (n = 85) harboring either R/H (filled diamond) or S/L (open circle) growth
phenotype viruses, or in 10 HIV-uninfected healthy controls (filled triangle). The mean systemic values of each cytokine (pg/ml) and CRP (μg/ml)
are compared in the figure for R/H and S/L viral phenotype groups. TNF-a, tumor necrosis factor-alfa; IFNg, interferon-gamma; IL-1a, interleukin-1
a; IL-4, interleukin-4; IL-6, interleukin-6; IL-10, interleukin-10; IL-17, interleukin 17; IL-22, interleukin-22; CRP, C-reactive protein. Extreme outlier data
points (IL-22) are not depicted for better visualization of results, but included into all calculations. *** = statistical difference of the medians, p <
0.001. The mean values of the measurements obtained from two independent experiments are shown.
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CRP and the disease status of HIV-1C-infected Indian
patients
Next we sought to lend support to the association
between cytokine production and the rate of viral repli-
cation in our in vitro model with in vivo data monitor-
ing disease progression. It is expected that a
combination of viral and host factors will determine
how fast can HIV replicate or overcome the immune
response in vivo, thus dictating the rate of progression
to AIDS in untreated patients. Therefore we calculated
the Spearman correlation coefficients for plasmatic
levels of IL-10, IL-22 and CRP and disease progression
as defined by patients’ viral load, CD4 cell counts, and
AIDS-defining conditions. For comparison, other clini-
cal syndromes not associated with late-stage disease
but highly prevalent in our study sample were also
evaluated. Additionally, the 95% confidence intervals
for the correlations were calculated to test the statisti-
cal significance of the correlation coefficients as
described in Methods. Table 2 shows the results of
these correlation analyses. The only significant correla-
tion found, as seen in the table, was between IL-22
titers and the presence of idiopatic chronic diarrhea, a
common finding of clinically latent or mildly sympto-
matic disease. The relevance of this finding will be dis-
cussed later in the paper. Meanwhile, we found no
correlation between the plasmatic titers of IL-10, IL-22
and CRP, and the disease progression markers studied.
However, this was not entirely surprising given the
polygenic and multifactorial nature of the disease, and
the difficulties in isolating the effect of individual
genes/proteins amongst unknown environmental and
genetic factors pertaining to both the human host and
the virus [48]. Even though the role in suppressing
HIV replication of several host factors (cytokines, b-
chemokines, chemokine receptors, APOBEC3G,
TRIM5a, TSG101, etc.) has been amply documented in
in vitro/ex vivo models, consistent associations with
progression to AIDS have not been observed in geneti-
cally diverse cohorts of patients [49-53]. Allelic varia-
tions of each host factor, genetic differences between
ethnicities and other factors have also confounded the
characterization of significant associations. Additionally,
one would expect that if the cytokine activity results in
slower HIV-1 replication in vitro,p r e s u m a b l yt h i s
would translate in lower viral loads in vivo;h o w e v e r ,
we must consider that several confounders affect this
Table 2 Lack of correlation between IL-10, IL-22 and CRP production and disease progression
IL-10 IL-22 CRP
r
(95% C.I.)
§
pr
(95% C.I.)
pr
(95% C.I.)
p
Viral load 0.213
(-0.004 - 0.411)
ns
¶ 0.118
(-0.102 - 0.327)
ns 0.010
(-0.207 - 0.226)
ns
CD4 count -0.146
(-0.349 - 0.071)
ns -0.073
(-0.283 - 0.144)
ns 0.018
(-0.197 - 0.231)
ns
AIDS-defining illness
a _
Pulmonary TB
† 0.041
(-0.174 - 0.252)
ns -0.005
(-0.218 - 0.207)
ns -0.054
(-0.264 - 0.161)
ns
Cryptosporidiosis
+;
isosporiasis
0.165
(-0.05 - 0.364)
ns 0.178
(-0.037 - 0.377)
ns 0.085
(-0.13 - 0.293)
ns
Wasting syndrome 0.122
(-0.094 - 0.326)
ns 0.101
(-0.115 - 0.307)
ns 0.161
(-0.054 - 0.362)
ns
Lymphoma -0.089
(-0.297 - 0.126)
ns 0.096
(-0.12 - 0.303)
ns -0.022
(-0.234 - 0.192)
ns
Other clinical Sx
‡
F.U.O.
⋇ 0.158
(-0.057 - 0.359)
ns 0.098
(-0.118 - 0.305)
ns 0.039
(-0.176 - 0.250)
ns
Chronic Diarrhea
o _ 0.172
(-0.043 - 0.371)
ns 0.388
(0.191 - 0.555)
<0.001 0.168
-0.047 - 0.231
ns
Constitutional
symptoms
0.015
(-0.199 - 0.227)
ns 0.033
(-0.181 - 0.244)
ns -0.093
(-0.3 - 0.123)
ns
§ r, Spearman correlation coefficient; 95% C.I., 95% confidence interval.
¶ ns, not significant (overall p-value of more than 0.05).
a _Clinical conditions listed in the AIDS surveillance case definition; only the most frequent in our study sample are shown.
† Pulmonary TB, pulmonary tuberculosis.
+Chronic, intestinal (> 1 month)
‡ Other clinical syndromes, non AIDS defining.
⋇ F.U.O., Fever of Unknown origin.
o _Idiopatic diarrhea, > 1 month.
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patients infected with HIV-1C have shown lower CD4
cell counts and higher viral loads than patients infected
with other subtypes in previous reports [7], are in
agreement with our results. Also several studies sup-
port a role for co-infecting pathogens in HIV disease.
For example, malaria episodes and TB infection result
in increase HIV viral load [54], and the latter has been
shown to accelerate the course of HIV [55]. An argu-
ment for TB is particularly relevant in India, where
HIV/TB co-infection rates are as high as 47% in Delhi
[56], and it has been shown to represent the etiology
of 63% of FUO cases [57,58]. Furthermore, viral load
does not predict in vitro infectivity, since current
methods routinely used for viral load measurements
determine the amount of genomic HIV-1 RNA copy
n u m b e r s ,b u tc a n n o td i s t i n g uish between infectious
and noninfectious or neutralized particles in plasma
[59]. We recognize that the lack of potential mechan-
isms to explain the effect of these cytokine phenotypes
in vivo warrants the need for additional studies; never-
theless, characterizing the small contribution of single
effects and developing multifactorial models that take
into account the combined effects of multiple variants
is out of the scope of the present work.
Effect of recombinant cytokine treatment on HIV-1C
replication kinetics in vitro
To further confirm the role of IL-10 and CRP in regu-
lating in vitro replication of HIV-1C, we tested the effect
on virus growth of pretreatment of virus expansion cul-
tures with maximum-response doses of CRP and recom-
binant human IL-10 either alone or in combination with
IL-6 and anti-IL mAb. IL-6 treatment was used to sti-
mulate virus production, and the blocking effect of neu-
tralizing doses of anti-IL-10 mAb was also evaluated.
The p24 production in all treatment schemes was com-
pared with untreated controls. As shown in Fig. 4, addi-
tion of recombinant IL-10 (5 ng/ml) to the media of
virus expansion cultures of representative R/H pheno-
type HIV-1C isolates showed a >10-fold reduction in
viral titers in vitro, which was statistically significant
(p = .009). This effect was partially abolished by co-incu-
bation with the stimulatory cytokine IL-6 (2.5 ng/ml).
Figure 4 IL-10 and CRP pre-treatment of viral expansion cultures downregulates HIV-1C replication in vitro. PHA-activated healthy-donor
PBMCs were pre-incubated with recombinant human IL-6 (2.5 ng/ml), IL-10 (5 ng/ml) or CRP (1 μg/ml), for 1 h before infection with a
representative R/H phenotype HIV-1C primary isolate, and HIV-1 p24 levels were determined by ELISA after 7 days of culture. Treatments
schemes are shown as follows: (1) Mock; (2) recombinant human (rh) IL-10; (3) rh CRP; (4) IL-6+IL-10; anti-IL-10 mAb+IL-10. The data are
representative of the results from two independent experiments. Results are shown as mean ± SD of relative p24 antigen production expressed
as percent of the mean p24 titer measured in the Mock-treated cultures. * = statistical difference of the medians, p < 0.05; ** = statistical
difference of the medians, p < 0.01; (ns) indicates that the p-value of the correlation coefficient was more than .05 (not significant).
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anti-HIV activity of IL-10 derives from its block on the
production of inflammatory cytokines [60]. Likewise, a
concentration equal to the ND50 dose of anti-IL10 also
restricted the negative effect of IL-10 on replication,
further highlighting the role of this cytokine in control-
ling viral growth. Additionally, CRP treatment (1 μg/ml)
also showed a lesser, yet significant inhibition of viral
replication (p = .021) in accordance with previous reports
that show that acute-phase proteins can have anti-HIV
activity [61].
Systemic IL-22 levels positively correlate with plasmatic
CRP and IL-10, and negatively with plasmatic LPS
Since IL-22 does not act on immune cells given that
lymphocytes lack IL-22 receptors [62], it was not possi-
ble to evaluate its effect on viral replication using the
same in vitro m o d e lt h a tw a sa p p l i e df o rI L - 1 0a n d
CRP; and therefore an alternative strategy was sought.
IL-22 is bi-functional with both pro-inflammatory and
protective effects on tissues depending on the inflamma-
tory context. As previously shown in Table 2, inspection
of the relationship between the cytokine response and
patient clinical manifestations revealed that IL-22 corre-
lated with chronic idiopatic diarrhea (p < .001), which is
interesting given that IL-22 appears to play an important
role in maintaining the integrity of the epithelium in
animal models of intestinal infection [63]. It has been
shown that higher circulating levels of bacterial bypro-
ducts (as a result of increased translocation into the
bloodstream) are associated with increased levels of
immune activation, which in turn correlates with
increased HIV-1 disease progression [64]. Subsequently
we measured the plasmatic levels of LPS, a component
of Gram-negative bacteria that acts as a marker of
microbial translocation from the gut, in all patients (n =
85), and in 10 HIV-uninfected healthy individuals for
comparison. As shown in Fig. 5A, we found statistically
significant lower plasma concentrations of LPS in
patients harboring S/L when compared to their R/H
Figure 5 Correlation between systemic IL-22 and plasmatic CRP, LPS and IL-10 levels. (A) Systemic LPS levels were evaluated by the LAL
assay, in plasma collected from HIV-1C-infected patients (n = 85) harboring either R/H (filled diamond) or S/L (open circle) growth phenotype
viruses, or in 10 HIV-uninfected healthy controls (filled triangle). The mean plasmatic LPS values (pg/ml) are compared in the figure for R/H and
S/L viral phenotype groups. Extreme outlier data points are not depicted for better visualization of results, but included into all calculations.
*** = statistical difference of the medians, p < 0.001. (B) Correlation between plasma LPS (pg/ml) and plasma IL-22 levels (pg/ml). (C) Correlation
between plasma IL-10 (pg/ml) and plasma IL-22 levels (pg/ml). (D) Correlation between plasma CRP (pg/ml) and plasma IL-22 levels (pg/ml) in
our study sample (n = 85). In all panels, r = Spearman correlation coefficient; p-value (two tailed);p-values of the correlation coefficient of less
than .05 were considered significant. The mean values of the measurements obtained from two independent experiments are shown.
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microbial translocation in the S/L group. LPS levels in
healthy controls were in the lower range of titers
reported in previous studies [34,65]. More importantly,
IL-22 showed a significant negative correlation with
plasmatic LPS (p = .001), as shown in Fig 5B, suggesting
ap r o t e c t i v er o l eo nt h ee p i t h e l i a lb a r r i e r .T a k e n
together, these results support the hypothesis that the
actions in mucosal host defense and epithelial barrier
protection described for IL-22 [66] are also required to
exert its anti-HIV actions, although its exact mechan-
isms of action are presently unknown.
On the other hand, the plasmatic levels of both IL-22
and IL-10 were also intrinsically correlated with each
other (Fig. 5C), and this association was statistically sig-
nificant (p < .001), as was the correlation between IL-22
and CRP (p = .002) as shown in Fig. 5D, but not
between IL-10 and CRP (p = .883, not shown). As
demonstrated before, both IL-10 and CRP significantly
inhibit HIV-1C replication in vitro,s ot h i sr e s u l ts u g -
gests that IL-22 might also mediate its anti-HIV effects
indirectly through association with IL-10 and CRP,
although the exact mechanisms remain unresolved.
Discussion
Reports of a reduced replication capacity of HIV-1C in
primary blood cells (CD4
+ T cells and PBMC) have led
some to suggest HIV-1C has low virulence [67]. How-
ever, reduced fitness in a reconstituted in vitro assay
does not necessarily imply that the corresponding virus
w i l lb el e s sf i ti nah u m a nh o s t ,s i n c ei nt h ein vivo
environment, a complex array of host factors can influ-
ence HIV-1 replication. Therefore, we believe that it is
impossible to discuss differences in the viral replication
of HIV-1C isolates without reference to the multidimen-
sional environment of the host from which they were
obtained.
The role of immunologic host factors has been widely
discussed in recent literature. HIV disease is described as
a disease of immune activation, yet the causes of immune
activation are not fully understood [68]. Conversely, lack
of immune activation has been shown to protect SIV-
infected sooty mangabeys (SM) and African green mon-
keys from progressing to AIDS [69]. It has also been
shown that production of cytokines (IL-2, TNFa,a n d
IFNg), particularly from dendritic cells, is quantitatively
reduced in SM compared to rhesus macaques and
that expression of IFNa is absent in SM [70]. This
modulation in response sets the stage for nonpathogenic
SIV-SM coexistence, while the same triggers in rhesus
macaques and humans result in generalized activation of
the immune system and immunopathogenesis.
Here we described 13 viral isolates showing high repli-
cation capacity in PBMC, a target in which HIV-1C is
reported to have low fitness. HIV-1C usage of the
CXCR4 co-receptor was rare and did not account for the
differences in replication between R/H and S/L viruses.
There was also no correlation between the in vitro repli-
cation kinetics of the isolates and all markers of disease
progression, but CD4 cell counts were low and viral
loads were high for both groups and in all stages of dis-
ease, in accordance with previous reports [7].
Most importantly, the data presented here show that
the ability of HIV-1C viruses to replicate efficiently in
activated healthy-donor PBMC is negatively associated
with plasmatic levels of IL-10 and IL-22, as well as the
inflammatory marker CRP in the corresponding
patients, and that treatment of viral expansion cultures
with recombinant IL-10, and CRP inhibits replication of
HIV-1C viruses in vitro.
This finding is consistent with previous reports that
showed the stimulation of monocyte-derived macro-
phages (MDM) with IL-10 significantly reduces HIV-1
production in those cells [22], and this inhibition is
associated with the ability of IL-10 to downregulate pro-
duction of IL-6 and TNFa [60]. Additional support for
the role of IL-10 on modulation of HIV-1 replication
comes from recent studies showing that IL-10-secreting
T cells downregulate HIV replication in pregnant
women [23] and elderly patients [71].
Conversely, CRP is an acute-phase reactant rapidly
synthesized in response to tissue injury, and it is widely
used as an unspecific indicator of an acute inflammatory
response. Its biological effects are similar to those of
immunoglobulins, precipitating, acting as a primitive
opsonin to bind to macrophages, and fixing comple-
ment, but it lacks immunomodifying actions [72].
Furthermore, an elevation in the baseline concentration
of CRP below 10 mg/l, like the one observed in this
study, is termed “low-grade inflammation” and consid-
ered to reflect housekeeping responses to distressed or
injured cells, rather than clinically significant inflamma-
tory conditions.
Perhaps the most interesting implication of this study
concerns the nature of the correlation between IL-22-in
association with IL-10 and CRP- and viral replication.
IL-22 is an important Th17 T-cell-associated cytokine
that mediates tissue responses during inflammation, but
it also has a role in the host response to infectious dis-
eases [63]. Importantly, the IL-22 receptor (IL-22R) is
highly expressed within tissues, primarily in epithelial
cells, but it is absent on immune cells; therefore, its acti-
vation has no direct effect on the immune response [73].
Even though little is known about the interaction
between IL-22 and IL10, at least one report suggests
that IL-22 induces IL-10 mRNA and protein production
in a colon epithelial cell line [74]. Therefore, one possi-
ble explanation for the anti-HIV effects of IL-22 could
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lack of systematic studies on whether IL-22 modulates
IL-10 effects or vice versa, this explanation remains
speculative.
Additionally, IL-22 has been shown to strongly induce
production of acute-phase proteins in the liver [74,75];
so it could be suggested that the minor elevations in the
baseline concentrations of CRP that we observed could
be explained by the inflammatory role of IL-22. In this
study, increased levels of IL-22 were reflected in a speci-
fic increase in plasmatic levels of CRP, confirming an
association between the biological functions of both
molecules. Of note, the secretion of CRP by hepatocytes
and epithelial cells is induced not only by IL-22, but
also by several other pro-inflammatory cytokines (IL-1,
IL-6, IL-17, TNF-a). However, as the immunoassay
results did not reveal high levels of the latter cytokines,
it is likely that the observed CRP levels result principally
from the action of IL-22.
Importantly, acute-phase proteins are reported to have
strong anti-infectious activity on some HIV-1 isolates
[61], and one of the mechanisms potentially implicated
is a downregulation of HIV-1 co-receptors. CRP has
been particularly implicated in a strong downregulation
of CCR5 [76], the main co-receptor used by HIV-1C
viruses. In our case this evidence is particularly relevant,
since IL-10, the other cytokine implicated in our study
does not affect the surface expression of CCR5 [77].
Therefore, another possible scenario would be that the
anti-HIV activity of IL-22 is indirectly mediated through
its downstream acute-phase products. Additional sup-
port for this hypothesis comes from a previous study
that showed that IL-22 is upregulated in repeatedly
exposed but uninfected individuals, concomitantly with
the acute-phase product serum amyloid protein-A,
which inhibited HIV infection of DCs in vitro [45].
Finally, the role of IL-22 on mediating protective host
responses against extracellular pathogens may contribute
t oi t sa n t i - H I Va c t i o n s .A sm e n t i o n e db e f o r e ,I L - 2 2
appears to play an important role in maintaining the
integrity of the epithelium. In murine models of intest-
inal infection with Citrobacter rodentium,t h e r ei s
greater intestinal damage in the absence of IL-22, lead-
ing to greater levels of systemic bacteria [63]. Indirect
support for this interpretation comes from recent stu-
dies showing that increased translocation of intestinal
bacterial byproducts into the circulation, is found in
advanced HIV-1 infection and is associated with an
increase in immune activation [34,78]. It is important to
n o t et h a ti nt h i ss t u d yw ef o u n dan e g a t i v ec o r r e l a t i o n
between systemic levels of IL-22 and plasmatic LPS, a
marker of microbial translocation. These results suggest
that protection of the intestinal epithelial barrier and
enhancement of wound repair conferred by IL-22
production are also critical elements of its anti-HIV
effects. This interpretation is partially supported by pre-
vious work showing that plasma LPS levels decrease
after initiating anti-retroviral therapy (ART), which sug-
gests an intrinsic relationship between reduced viral
replication and integrity of the intestinal mucosa,
although the exact molecular mechanisms involved
remain unresolved.
The findings presented here support the role of IL-10
in controlling viral replication, and provide a starting
point for further investigation of the influence of IL-22
and CRP on HIV replication. There are obvious limita-
tions in our work, as it would have been desirable to
evaluate directly if there were any differences in cytokine
production between the PBMC of S/L and R/H subjects,
or differences in the surface expression of CCR5
between those groups, since this data would better sup-
port some of the findings and conclusions presented
here. Unfortunately, due to problems in the practical
implementation of patient collection and low return
rates, we could not address these questions. Despite
these reservations, we feel our preliminary findings sug-
gest an interesting avenue for research on HIV-1C
pathogenesis, and some of the questions raised warrant
further investigation.
Conclusions
In summary, the present study supports the hypothesis
that high systemic levels of IL-10, IL-22 and CRP in
HIV-1C-infected Indian patients correlate with a
reduced replication in vitro. This triad sets up an envir-
onment characterized by an IL-10-mediated immuno-
suppressive profile that reduces immune activation, in
concert with a subclinical inflammatory response of per-
ipheral tissues mediated by IL-22 and CRP. Additionally,
both IL-10 and CRP demonstrate a direct inhibitory
effect on the in vitro replication of HIV-1C viruses,
whereas IL-22 appears to exert its effect through down-
stream mechanisms that are still not well understood,
but that include both its inflammatory and protective
actions. The anti-HIV action of IL-10 has been widely
documented, but to the best of our knowledge this is
the first study reporting preliminary evidence of an asso-
ciation of IL-22 and CRP with low viral replication.
However, the molecular and cellular mechanisms under-
lying the difference in cytokine production between
patients harboring R/H or S/L viruses, the logistics of
cooperation between IL-22, IL-10 and CRP, as well as
the correlation between intestinal protection conferred
by IL-22 and control of viral replication, remain elusive
and will be the subject of future investigation. We hope
that in the future, a better understanding of the
mechanisms responsible for the inhibition of viral repli-
cation exerted by IL-10, IL-22 and CRP will provide
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Page 12 of 15advances in our understanding of the pathogenesis of
AIDS and eventually translate into future therapeutic
strategies to be used in concert with ART in HIV-
infected individuals.
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